Thu 25 Jun 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
| Product | Date | Safety information | Attachments |
|---|---|---|---|
| Jectin-12® (Cyanocobalamin) | Cyanocobalamin and the risk of medication error. |
||
| Xeljanz® (Tofacitinib) | Increased risk of pulmonary embolism and overall mortality with higher dose of XELJANZ (tofacitinib) for rheumatoid arthritis. |
||
| Genvoya ® (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide) | Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection due to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy. |
||
| Dapagliflozin | Risk of Fournier’s gangrene (necrotising fasciitis of the perineum) with Sodium-glucose-Co-Transporter 2 inhibitors (SGLT2i). |
||
| Adenuric® (Febuxostat) | Febuxostat (adenuric®): Higher rate of cardiovascular death in gout patients with established cardiovascular disease. |
||
| Belimumab | Benlysta (Belimumab) and Risk of serious Depression and/ or Suicidal ideation or Behavior or self-injury. |
||
| Atezolizumab | TECENTRIQ® (atezolizumab): A New Important Identified Risk: Immune-related Myositis. |
||
| Canagliflozin | Risk of Fournier´s gangrene (necrotising fasciitis of the perineum) with Sodium-Glucose-Co-Transporter 2 inhibitors (SGLT2i). |
||
| Pembrolizumab | Keytruda (pembrolizumab): Restriction of indication for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy. |
||
| Empagliflozin | Direct Healthcare Professional Communication on the association of Sodium-Glucose-Co-Transporter 2 inhibitors (SGLT2i) with Risk of Fournier´s gangrene (necrotising fasciitis of the perineum). |
Last update date: 21/04/2024 at 10:00 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.